Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Decousus

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
Thrombosis and Haemostasis|February 11, 2000
Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trialsP Mismetti, S Laporte-Simitsidis, B Tardy, et al.
Archives of Internal Medicine|July 12, 1993
Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosisG Simonneau, B Charbonnier, H Decousus, et al.
British Journal of Clinical Pharmacology|May 19, 2007
Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldA Berges, S Laporte, M Epinat, et al.
Presse Medicale (Paris, France : 1983)|May 15, 1993
[Phlebitis following travel]B Tardy, Y Page, F Zeni, et al.
Haemostasis|March 17, 2001
A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in ratsD Abrial, A Blanc, M Réhailia, et al.
British Journal of Haematology|January 1, 1997
Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double-blind randomized studyB Tardy, B Tardy-Poncet, S Laporte-Simitsidis, et al.
Gastroenterologie Clinique Et Biologique|November 1, 1995
[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease]F Fontaney, A Dacosta, J F Mosnier, et al.
International Angiology : a Journal of the International Union of Angiology|February 15, 2012
Natural history of patients developing thrombocytopenia while receiving anticoagulant therapy for venous thromboembolismP Di Micco, A Fontanella, N Falvo, et al.
Chronobiology International|April 11, 2000
Establishing the dose-dependent daily variations of a low molecular weight heparin (Fraxiparine) through a population approach analysis in the ratD Abrial, A Blanc, M Réhailia, et al.
Thrombosis and Haemostasis|August 1, 1995
Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteersP Mismetti, J Reynaud, B Tardy-Ponce, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Thrombosis and Haemostasis|February 11, 2000
Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trialsP Mismetti, S Laporte-Simitsidis, B Tardy, et al.
Archives of Internal Medicine|July 12, 1993
Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosisG Simonneau, B Charbonnier, H Decousus, et al.
British Journal of Clinical Pharmacology|May 19, 2007
Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years oldA Berges, S Laporte, M Epinat, et al.
Presse Medicale (Paris, France : 1983)|May 15, 1993
[Phlebitis following travel]B Tardy, Y Page, F Zeni, et al.
Haemostasis|March 17, 2001
A chronopharmacodynamic study on standard heparin, a low molecular weight heparin (nadroparin) and danaproid: establishing and comparing the daily variations of these drugs in ratsD Abrial, A Blanc, M Réhailia, et al.
British Journal of Haematology|January 1, 1997
Evolution of blood coagulation and fibrinolysis parameters after abrupt versus gradual withdrawal of acenocoumarol in patients with venous thromboembolism: a double-blind randomized studyB Tardy, B Tardy-Poncet, S Laporte-Simitsidis, et al.
Gastroenterologie Clinique Et Biologique|November 1, 1995
[Inflammatory pseudotumor of the intestine caused by necrotizing vasculitis in the course of Horton disease]F Fontaney, A Dacosta, J F Mosnier, et al.
International Angiology : a Journal of the International Union of Angiology|February 15, 2012
Natural history of patients developing thrombocytopenia while receiving anticoagulant therapy for venous thromboembolismP Di Micco, A Fontanella, N Falvo, et al.
Chronobiology International|April 11, 2000
Establishing the dose-dependent daily variations of a low molecular weight heparin (Fraxiparine) through a population approach analysis in the ratD Abrial, A Blanc, M Réhailia, et al.
Thrombosis and Haemostasis|August 1, 1995
Chrono-pharmacological study of once daily curative dose of a low molecular weight heparin (200 IU antiXa/kg of Dalteparin) in ten healthy volunteersP Mismetti, J Reynaud, B Tardy-Ponce, et al.
Pageof 8